Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

607
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
607
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
Drug Therapy01:28

Drug Therapy

74
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
74
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

171
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
171
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

197
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
197

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spinal solitary fibrous tumor metastatic to the fourth ventricle: illustrative case.

Journal of neurosurgery. Case lessonsยท2026
Same author

Long-Term Mechanical Complications After Lumbar Fusion in Patients Receiving Tirzepatide vs Other GLP-1 Receptor Agonists.

Spineยท2026
Same author

Discriminating HFrEF vs HFpEF from chest radiographs: Mitigating demographic performance gaps via augmentation and multimodal fusion.

PLOS digital healthยท2026
Same author

Parkinson's disease increases readmission, non-routine discharge, and length of stay following primary cervical fusion.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasiaยท2026
Same author

Surgical re-evaluation patterns among pediatric vagus nerve stimulation non-responders: a single-center retrospective study.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgeryยท2026
Same author

Long-Term Risk of Subsequent Cervical Fusion After Endoscopic Versus Open Cervical Decompression.

Global spine journalยท2026

Related Experiment Video

Updated: Jul 25, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K

Parkinson's disease - current treatment.

Ryan Wang1, Ludy C Shih1,2

  • 1Department of Neurology, Boston Medical Center.

Current Opinion in Neurology
|June 27, 2023
PubMed
Summary

Recent Parkinson's disease (PD) research offers improved treatments for motor symptoms like fluctuations and dyskinesia. New therapies also show promise for non-motor symptoms, enhancing patient quality of life.

More Related Videos

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.5K
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.5K

Related Experiment Videos

Last Updated: Jul 25, 2025

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.5K
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.5K

Area of Science:

  • Neurology
  • Movement Disorders
  • Geriatrics

Background:

  • Parkinson's disease (PD) presents complex motor and non-motor symptoms impacting patient quality of life.
  • Optimal symptomatic management is crucial, as current treatments do not halt disease progression.

Approach:

  • Review of recent studies on therapeutic advancements for Parkinson's disease.
  • Analysis of new formulations and strategies for both motor and non-motor symptom management.

Key Points:

  • Optimized levodopa formulations reduce motor fluctuations and dyskinesia.
  • On-demand apomorphine effectively manages motor off-periods.
  • Emerging treatments show promise for constipation, sleep disorders, and oropharyngeal dysphagia.
  • Advanced deep brain stimulation techniques offer a wider therapeutic window.

Conclusions:

  • While disease-modifying treatments are lacking, significant progress is being made in symptomatic management of Parkinson's disease.
  • Clinicians must stay informed about evolving therapeutic options to address the multifaceted challenges of PD.